创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: Introducing the Advantages of the GVHD Experimental Platform

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-01-29 15:47
  • Views:

(Summary description)The GVHD (Graft Versus Host Disease) Experimental Platform from InnoModels Biotechnology is the company's innovative product in the field of transplantation medicine, providing researchers with powerful tools to gain insights into the pathogenesis of GVHD, evaluation of potential treatments, and drug screening

InnoModels Biotechnology: Introducing the Advantages of the GVHD Experimental Platform

(Summary description)The GVHD (Graft Versus Host Disease) Experimental Platform from InnoModels Biotechnology is the company's innovative product in the field of transplantation medicine, providing researchers with powerful tools to gain insights into the pathogenesis of GVHD, evaluation of potential treatments, and drug screening

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-01-29 15:47
  • Views:
Information

The GVHD (Graft Versus Host Disease) Experimental Platform from InnoModels Biotechnology is the company's innovative product in the field of transplantation medicine, providing researchers with powerful tools to gain insights into the pathogenesis of GVHD, evaluation of potential treatments, and drug screening. The following are some of the significant advantages of the platform:
1. Humanized Model: The GVHD experimental platform from InnoModels Biotechnology uses a humanized cell model to simulate what actually happens in transplantation medicine. This enables researchers to more accurately understand the process of GVHD in the human body, providing a stronger basis for drug discovery and therapeutic development.
2. Multi-dimensional experimental parameters: The platform supports multi-dimensional experimental parameters, including the type of immune cells, the source of grafts, and the amount of grafts. Researchers can adjust these parameters according to their specific research needs to simulate different GVHD pathologies and further deepen their understanding of GVHD mechanisms.
3. Adjustable experimental conditions: InnoModels Biotechnology provides adjustable experimental conditions for the GVHD experimental platform, including medium composition, cell density, incubation time, and so on. This adjustability helps researchers to simulate different experimental conditions, improving the flexibility and reproducibility of experiments.

 


4. Highly reproducible: The platform is highly reproducible, ensuring consistent results. This is very important for researchers to compare and validate between different laboratories at different points in time, helping to ensure the scientific reliability of research results.
5. Real-time monitoring and analysis: The GVHD experimental platform is equipped with real-time monitoring and data analysis functions, enabling researchers to instantly understand the development process of GVHD. This helps early detection of potential therapeutic effects, as well as optimization of treatment options.
6. Support for high-throughput experiments: The platform supports high-throughput experiments, which can handle multiple samples at the same time and improve the efficiency of experiments, especially suitable for drug screening and disease treatment research.
7. Professional technical support: InnoModels Biotechnology provides users with professional technical support, including experimental design, data analysis and other support, to ensure that users can make full use of the GVHD platform to carry out high-quality research work.
By providing this advanced GVHD experimental platform, InnoModels Biotechnology provides researchers in the field of transplantation medicine with a powerful tool to promote in-depth research on the mechanism of GVHD and lay a solid foundation for the development of related therapeutic methods.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司